Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAXIBACUMAB vs ARZERRA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Raxibacumab is a monoclonal antibody that binds to the protective antigen (PA) component of Bacillus anthracis toxins, preventing PA from binding to host cell receptors and thereby inhibiting the intracellular entry of lethal factor and edema factor. This neutralizes the lethal and edema toxins, reducing pathogenicity.
Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.
Inhalational anthrax: Treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs,Inhalational anthrax prophylaxis: Prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate
Treatment of chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab,Treatment of previously untreated CLL in combination with chlorambucil,Treatment of relapsed CLL in combination with fludarabine and cyclophosphamide
Single intravenous dose of 40 mg/kg administered over 30 minutes.
ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.
Terminal elimination half-life approximately 12-24 hours (mean ~18 hours) in patients with normal renal function; half-life extends in renal impairment.
Mean terminal elimination half-life after first dose is approximately 14 days (range 7–21 days) and increases with repeated dosing due to target-mediated clearance saturation; at steady state, half-life is ~24 days.
Monoclonal antibodies are generally degraded into small peptides and amino acids via catabolic pathways, similar to endogenous immunoglobulins. Raxibacumab metabolism is not mediated by hepatic CYP450 enzymes.
Ofatumumab is a monoclonal antibody; metabolism is not through typical cytochrome P450 pathways. Clearance involves catabolism to peptides and amino acids.
Primarily renal excretion as intact protein; >90% of administered dose recovered in urine over 48 hours.
Arzerra (ofatumumab) is eliminated primarily via the reticuloendothelial system and catabolism; renal excretion is minimal (<1% of dose as intact antibody). Biliary/fecal excretion has not been characterized, but as a monoclonal antibody, it is not significantly excreted in urine or feces.
Negligible protein binding (<1% bound) as a monoclonal antibody.
As a monoclonal antibody, ofatumumab does not bind to plasma proteins; protein binding is negligible.
Volume of distribution approximately 0.15 L/kg, indicating limited extravascular distribution consistent with a large protein.
Volume of distribution (Vd) is approximately 2.5–4.5 L, approximating plasma volume; does not distribute extensively into tissues (not reported in L/kg, but typical for Ig G1 monoclonal antibodies ~0.1–0.2 L/kg).
Intravenous: 100%; Subcutaneous: Approximately 60-70% (mean ~65%).
Subcutaneous: ~60–70% absolute bioavailability; intravenous: 100%.
No dosage adjustment required for any degree of renal impairment including end-stage renal disease.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or hemodialysis; use with caution.
No dosage adjustment required for any degree of hepatic impairment.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C); use with caution.
Safety and efficacy in pediatric patients have not been established.
Safety and efficacy in pediatric patients (<18 years) have not been established; no recommended dosing.
No specific dosage adjustment recommended; clinical studies included limited number of patients aged 65 and older.
No specific dose adjustment required for elderly patients. Clinical studies included patients ≥65 years; overall efficacy and safety similar to younger adults, but higher incidence of serious infections and cardiac events observed.
None.
Hepatitis B virus (HBV) reactivation can occur with ofatumumab, leading to fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before initiation. Monitor HBV carriers during and after treatment.
Hypersensitivity reactions, including anaphylaxis, have been reported. Monitor patients during infusion and have appropriate medical support available.,Infusion-related reactions (e.g., urticaria, pruritus, rash) may occur. Slow or stop infusion if severe.,Interference with immune response: As a monoclonal antibody, may interfere with the immune response to anthrax vaccination. Use with caution.,Limited clinical data: Efficacy is based on animal models; clinical efficacy in humans is not established.
Infusion reactions (including anaphylaxis), prolonged cytopenias, progressive multifocal leukoencephalopathy (PML), intestinal obstruction, tumor lysis syndrome, and infections including hepatitis B reactivation.
None.
Known hypersensitivity (anaphylaxis) to ofatumumab or any of its excipients.
No known food interactions. Take with or without food.
No known food interactions. Take with or without food.
FDA Pregnancy Category C. Animal studies show embryotoxicity at high doses; no adequate human studies. Avoid in pregnancy unless benefit outweighs risk. First trimester: potential for teratogenicity; second and third trimesters: risk of fetal hemorrhage due to antiplatelet effect.
ARZERRA (ofatumumab) is a human monoclonal antibody. Ig G molecules cross the placenta increasingly after the first trimester. Based on its mechanism of action (B-cell depletion), there is a potential risk of fetal B-cell lymphocytopenia and impaired immune response. Data from animal studies are insufficient. The drug should be avoided during pregnancy unless the benefit clearly outweighs the risk.
Unknown if excreted in human breast milk. M/P ratio not determined. Due to long half-life and potential for bleeding, caution advised; consider discontinuing breastfeeding during therapy.
It is unknown whether ofatumumab is excreted in human milk. Human Ig G is present in breast milk, but levels are low. Due to the potential for serious adverse reactions in the breastfed infant (including B-cell depletion), breastfeeding is not recommended during therapy and for at least 6 months after the last dose. No M/P ratio is available.
No specific studies; pharmacokinetics may be altered due to increased plasma volume and renal clearance. Use lowest effective dose; consider dose reduction based on platelet count and bleeding risk.
No specific dose adjustment guidelines are established for pregnancy. The pharmacokinetics of monoclonal antibodies may be altered due to increased plasma volume and clearance in pregnancy, but no formal studies have been conducted. Use caution and consider therapeutic drug monitoring if available.
Raxibacumab is a monoclonal antibody indicated for inhalation anthrax and prophylaxis when alternative therapies are unavailable. Administer intravenously over 2 hours and 15 minutes. Premedication with diphenhydramine is recommended to reduce infusion reactions. Monitor for anaphylaxis. Not effective for cutaneous anthrax. Use in pregnancy only if benefit outweighs risk.
ARZERRA (ofatumumab) is a monoclonal antibody targeting CD20 used in relapsing multiple sclerosis. First dose reactions are common; premedicate with corticosteroids, antihistamines, and antipyretics. Monitor for infections, especially hepatitis B reactivation. Contraindicated in active hepatitis B. Administer as subcutaneous injection; injection site reactions frequent. Live vaccines contraindicated during and after treatment until immune reconstitution.
This medication is given as an intravenous infusion for anthrax infection or prevention.,You will receive premedication to reduce the risk of allergic reactions.,Report any symptoms of allergic reaction such as hives, itching, difficulty breathing, or swelling during infusion.,This drug is not a vaccine and does not provide long-term protection.,Complete the full course of treatment as prescribed even if you feel better.
Report any signs of infection (fever, chills, cough, painful urination) promptly.,Inform your doctor of any history of hepatitis B infection.,You will receive premedication before the first dose to reduce allergic reactions.,Do not receive live vaccines during treatment or until your doctor confirms immune recovery.,Common side effects include injection site reactions, headache, and fever.,ARZERRA is given as an injection under the skin; rotation of injection sites is recommended.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAXIBACUMAB vs ARZERRA, answered by our medical review team.
RAXIBACUMAB is a Monoclonal Antibody that works by Raxibacumab is a monoclonal antibody that binds to the protective antigen (PA) component of Bacillus anthracis toxins, preventing PA from binding to host cell receptors and thereby inhibiting the intracellular entry of lethal factor and edema factor. This neutralizes the lethal and edema toxins, reducing pathogenicity.. ARZERRA is a Antineoplastic, Monoclonal Antibody that works by Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAXIBACUMAB and ARZERRA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAXIBACUMAB is: Single intravenous dose of 40 mg/kg administered over 30 minutes.. The standard adult dose of ARZERRA is: ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAXIBACUMAB and ARZERRA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAXIBACUMAB is classified as Category C. FDA Pregnancy Category C. Animal studies show embryotoxicity at high doses; no adequate human studies. Avoid in pregnancy unless benefit outweighs risk. First trimester: potential . ARZERRA is classified as Category C. ARZERRA (ofatumumab) is a human monoclonal antibody. IgG molecules cross the placenta increasingly after the first trimester. Based on its mechanism of action (B-cell depletion), t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.